PRESTIGE CONSUMER HEALTHCARE INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $54.72 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-06-30 was $54.72.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-06-30 was $54.47.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2021-06-30 was $56.63.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2026 was $65.56.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $54.47, a 27.77% increase from fiscal 2023.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $42.63, a 24.72% decline from fiscal 2022.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $56.63, a 7.13% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $54.72 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $65.56 10-K · filed 2026-05-14 | ||||
| 2025-12-31 | $65.56 10-Q · filed 2026-02-05 | ||||
| 2024-03-31 | $54.47 10-K · filed 2026-05-14 | ||||
| 2023-12-31 | $54.47 10-Q · filed 2025-02-06 | ||||
| 2023-09-30 | $54.47 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | $54.47 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | $42.63 10-K · filed 2025-05-09 | $44.33 10-K · filed 2023-05-05 | |||
| 2022-12-31 | $44.33 10-Q · filed 2024-02-08 | ||||
| 2022-03-31 | $56.63 10-K · filed 2024-05-15 | ||||
| 2021-12-31 | $56.63 10-Q · filed 2023-02-02 | ||||
| 2021-09-30 | $56.63 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | $56.63 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $52.86 10-K · filed 2023-05-05 | ||||
| 2020-12-31 | $0.00 10-Q · filed 2022-02-03 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | ||||
| 2020-03-31 | $50.31 10-K · filed 2022-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |